Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jbmt.2024.05.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ISCT MSC committee statement on the US FDA approval of allogenic bone-marrow mesenchymal stromal cells.
Cytotherapy
January 2025
Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada; Krembil Research Institute, University Health Network, Toronto, Ontario, Canada; Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, Division of Hematology, University of Toronto, Toronto, Ontario, Canada. Electronic address:
The December 2024 US Food and Drug Administration (FDA) approval of Mesoblast's Ryoncil (remestemcel-L-rknd)-allogeneic bone marrow mesenchymal stromal cell (MSC(M)) therapy-in pediatric acute steroid-refractory graft-versus-host-disease finally ended a long-lasting drought on approved MSC clinical products in the United States. While other jurisdictions-including Europe, Japan, India, and South Korea-have marketed autologous or allogeneic MSC products, the United States has lagged in its approval. The sponsor's significant efforts and investments, working closely with the FDA addressing concerns regarding clinical efficacy and consistent MSC potency through an iterative process that spanned several years, was rewarded with this landmark approval.
View Article and Find Full Text PDFPreoperative anxiety and depression are associated with poorer patient-reported outcomes following total ankle replacements.
Foot Ankle Surg
January 2025
Edinburgh Orthopaedics, Royal Infirmary of Edinburgh, Little France Crescent, Edinburgh EH16 4SA, United Kingdom.
Introduction: It is unclear how pre-operative anxiety/depression affects patient reported outcome measures (PROMs) following total ankle replacements (TAR). We investigated the effects of anxiety/depression on PROMs using the Manchester-Oxford Foot Questionnaire (MOXFQ) following TAR.
Methods: PROMs data for primary TAR patients between 2011 and 2022 were extracted from a single-centre regional registry.
Animal models of disease: Achievements and challenges.
Methods Cell Biol
January 2025
Fox Chase Cancer Center, Philadelphia, PA, United States. Electronic address:
Higher Levels of Glucose within the Normal Range and Cardiovascular Risk: A Landscape Beyond Diabetes and Prediabetes.
Am Heart J
January 2025
Division of Cardiology, Geffen School of Medicine at University of California, Los Angeles, California, United States. Electronic address:
Are AI chatbots concordant with evidence-based cancer screening recommendations?
Patient Educ Couns
January 2025
Wiser Healthcare, Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Australia; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, NSW, Australia.
Objective: This study aimed to assess whether information from AI chatbots on benefits and harms of breast and prostate cancer screening were concordant with evidence-based cancer screening recommendations.
Methods: Seven unique prompts (four breast cancer; three prostate cancer) were presented to ChatGPT in March 2024. A total of 60 criteria (30 breast; 30 prostate) were used to assess the concordance of information.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!